Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 369

1.

Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.

Jamaluddin EJ, Gafor AH, Yean LC, Cader R, Mohd R, Kong NC, Shah SA.

Clin Exp Nephrol. 2014 Jun;18(3):507-14. doi: 10.1007/s10157-013-0844-2. Epub 2013 Aug 2.

PMID:
23903802
2.

Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.

Ong LM, Narayanan P, Goh HK, Manocha AB, Ghazali A, Omar M, Mohamad S, Goh BL, Shah S, Seman MR, Vaithilingam I, Ghazalli R, Rahmat K, Shaariah W, Ching CH; Oral Paricalcitol in ESRD Study Group.

Nephrology (Carlton). 2013 Mar;18(3):194-200. doi: 10.1111/nep.12029.

PMID:
23311404
3.

Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.

Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L.

Ren Fail. 2012;34(3):297-303. doi: 10.3109/0886022X.2011.647298. Epub 2012 Jan 17.

PMID:
22251408
4.

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.

Am J Nephrol. 2008;28(1):97-106. Epub 2007 Oct 3.

PMID:
17914251
5.

Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.

Abdul Gafor AH, Saidin R, Loo CY, Mohd R, Zainudin S, Shah SA, Norella KC.

Nephrology (Carlton). 2009 Aug;14(5):488-92. doi: 10.1111/j.1440-1797.2008.01058.x. Epub 2009 Mar 10.

PMID:
19298641
6.

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.

Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.

Am J Kidney Dis. 2007 Jun;49(6):814-23.

PMID:
17533024
7.

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.

Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J.

J Am Soc Nephrol. 1998 Aug;9(8):1427-32.

8.

Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.

Vulpio C, Maresca G, Distasio E, Cacaci S, Panocchia N, Luciani G, Bossola M.

Hemodial Int. 2011 Jan;15(1):69-78. doi: 10.1111/j.1542-4758.2010.00514.x. Epub 2011 Jan 12.

PMID:
21223484
9.

Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.

Borrego Utiel FJ, Bravo Soto JA, Merino Pérez MJ, González Carmelo I, López Jiménez V, García Álvarez T, Acosta Martínez Y, Mazuecos Blanca MA.

Nefrologia. 2015;35(4):363-73. doi: 10.1016/j.nefro.2015.06.018. Epub 2015 Aug 4. English, Spanish.

10.

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.

Llach F, Yudd M.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S45-50.

PMID:
11689387
11.

Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.

Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S.

Nephrol Dial Transplant. 2014 Apr;29(4):899-905. doi: 10.1093/ndt/gfu011. Epub 2014 Feb 4.

PMID:
24500308
12.

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.

Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S.

Nephrol Dial Transplant. 2012 Aug;27(8):3270-8. doi: 10.1093/ndt/gfs018. Epub 2012 Mar 2.

13.

Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.

Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.

J Nephrol. 2009 Jan-Feb;22(1):59-68.

PMID:
19229819
14.

Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.

Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E.

Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S48-54.

PMID:
9808143
15.

Intraperitoneal pulse calcitriol in the treatment of secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.

Chan HW, Tsang WK, Chan CM, Fung SK, So SO, Tang HL, Tong MK, Lee KC, Chan AY.

Perit Dial Int. 1998 Mar-Apr;18(2):177-82.

PMID:
9576366
16.

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.

Seeherunvong W, Nwobi O, Abitbol CL, Chandar J, Strauss J, Zilleruelo G.

Pediatr Nephrol. 2006 Oct;21(10):1434-9. Epub 2006 Aug 10.

PMID:
16900383
17.

Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.

Fernström A, Giæver J, Granroth B, Hylander B, Jensen G, Christensson A, Wikström B, Weiss L, Wrege U, Jacobson SH.

Scand J Urol Nephrol. 2011 Apr;45(3):196-205. doi: 10.3109/00365599.2011.553738. Epub 2011 Mar 2.

PMID:
21366390
18.

Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.

Biggar P, Kovarik J, Klauser-Braun R, Graf H, Müller HW, Veres A, Seidinger S, Ketteler M.

Nephron Clin Pract. 2014;126(1):39-50. doi: 10.1159/000357677. Epub 2014 Jan 17.

PMID:
24458019
19.
20.

Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.

Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S.

Ther Apher Dial. 2007 Jun;11(3):202-9.

PMID:
17498002

Supplemental Content

Support Center